rHuPH20 clinical trials

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

This study is looking at a new way to give medicine for advanced melanoma. We want to see if an injection under the skin works as well as the usual drip into a vein. This might make treatment easier for patients.